Epigenomics AG represents the values of innovation, excellence, and integrity. The company is dedicated to developing and commercializing innovative solutions for the early detection and diagnosis of cancer through its proprietary biomarker technology. Epigenomics AG is committed to providing reliable and accurate diagnostic products that empower healthcare professionals and improve patient outcomes. With a focus on research and development, the company strives to stay at the forefront of epigenetics and molecular diagnostics. Epigenomics AG believes in fostering collaboration, transparency, and ethical business practices to ensure the highest standards in its operations and interactions with stakeholders.

Epigenomics AG, a leading biotechnology company, is primarily present in various countries and regions around the globe. With its headquarters in Germany, Epigenomics AG has established a strong presence in Europe. Additionally, the company has expanded its operations to North America, including the United States and Canada, where it actively engages in research, development, and commercialization of innovative diagnostic products. Epigenomics AG's global reach also extends to other key markets, catering to healthcare professionals and patients worldwide. This international presence underscores the company's commitment to advancing precision medicine and improving patient outcomes on a global scale.

Epigenomics AG has achieved several significant milestones since its inception. The company gained approval from the U.S. Food and Drug Administration (FDA) for its blood-based colorectal cancer screening test, Epi proColon®. This breakthrough marked a pivotal moment, providing a non-invasive alternative to traditional colonoscopy. Epigenomics AG also secured partnerships with leading diagnostic and pharmaceutical companies, facilitating global distribution of their products. Furthermore, the company's research and development efforts have resulted in numerous patent grants, reinforcing their position as a leader in the field of epigenetics-based diagnostics. These milestones highlight Epigenomics AG's commitment to advancing innovative solutions for cancer screening and detection.

Epigenomics AG is a renowned biotechnology company specializing in cancer diagnosis and personalized medicine. Founded in 1998, the company has since established itself as a global leader in the field of epigenetics. Epigenomics AG focuses on the development and commercialization of innovative diagnostic tests for early detection and prognosis of various types of cancer, including colorectal and lung cancer. With an extensive portfolio of patents and expertise in molecular diagnostics, Epigenomics AG continues to drive advancements in the field, enabling improved patient outcomes and disease management. Its dedication to precision medicine and cutting-edge research positions Epigenomics AG as a vital player in the fight against cancer.

The main competitors of Epigenomics AG in the market include Genomic Health, Exact Sciences Corporation, and Myriad Genetics.

Epigenomics AG is primarily active in the healthcare and biotechnology industries.

The business model of Epigenomics AG is focused on the development and commercialization of innovative tests for the early detection and diagnosis of cancer. Epigenomics AG primarily utilizes its proprietary epigenetic biomarker technology to identify and analyze DNA methylation patterns, which can serve as indicators for various types of cancer. By collaborating with partners and leveraging its expertise in molecular diagnostics, Epigenomics AG aims to provide non-invasive and accurate diagnostic solutions that enable personalized and effective cancer treatment. Through its business model, Epigenomics AG strives to make a positive impact in the field of cancer detection and improve patient outcomes.

The Epigenomics P/E ratio is -0.72.

The Epigenomics P/S ratio is 1.88.

The Quality Investing for Epigenomics is 3/10.

The expected Epigenomics revenue is 303,000 EUR.

The expected Epigenomics profit is -791,031.96 EUR.

Epigenomics AG is a biotechnology company specializing in the development of diagnostic tests for cancer. The company was founded in 1997 and is headquartered in Berlin, Germany. Epigenomics offers various products and services based on DNA methylation analysis technology, which allows for the quick and precise detection of cancer cells based on DNA changes. One important part of Epigenomics' business model is the development of in vitro diagnostics (IVD) that can be used by doctors and hospitals for cancer diagnosis. The company has developed an IVD platform that can detect specific DNA methylation changes that may indicate the presence of cancer. This platform is capable of diagnosing up to seven different types of cancer, including colorectal, lung, and prostate cancer. Another aspect of Epigenomics' business model is providing services to pharmaceutical companies involved in the development of cancer drugs. Epigenomics offers its customers the opportunity to conduct biomarker tests to study the effectiveness of cancer drugs. Additionally, the company works closely with pharmaceutical companies to validate its technology in clinical trials. Collaboration with other companies and academic institutions in cancer research and other diseases is another important aspect of Epigenomics' business model. Epigenomics works with partners in Europe, North America, Asia, and the Middle East to conduct research projects and clinical trials. Epigenomics is a publicly traded company and generates a portion of its revenue through the sale of products and services. The company also collaborates with various government agencies and organizations to advance its technology in cancer diagnostics. Epigenomics has also filed patents for its technology to protect its intellectual property rights. Overall, Epigenomics has established itself as a leading company in cancer diagnostics, developing innovative technologies and solutions to improve cancer diagnosis. The company has made significant progress in recent years and aims to continue playing a leading role in the field of cancer diagnostics.

Epigenomics pays a dividend of 0 EUR distributed over payouts per year.

The dividend cannot currently be calculated for Epigenomics or the company does not pay out a dividend.

The ISIN of Epigenomics is DE000A3H2184.

The WKN of Epigenomics is A3H218.

The ticker of Epigenomics is ECX.DE.

Over the past 12 months, Epigenomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Epigenomics is expected to pay a dividend of 0 EUR.

The current dividend yield of Epigenomics is .

Epigenomics pays a quarterly dividend. This is distributed in the months of .

Epigenomics paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

Epigenomics is assigned to the 'Health' sector.

To receive the latest dividend of Epigenomics from 12/17/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

The last dividend was paid out on 12/17/2024.

In the year 2023, Epigenomics distributed 0 EUR as dividends.

The dividends of Epigenomics are distributed in EUR.